Related Experiment Video

Updated: Apr 26, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K

Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma

James S Blachly1, Robert A Baiocchi

  • 1Division of Hematology, Department of Internal Medicine and The Ohio State University James Comprehensive Cancer, The Ohio State University, Columbus, OH, USA.

British Journal of Haematology
|August 8, 2014
PubMed

Insights

Targeted therapies are revolutionizing oncology. This review explores Phosphatidylinositol 3-kinase (PI3K) pathway inhibitors, crucial for treating lymphoma and other cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Targeted therapy offers a paradigm shift from traditional cytotoxic treatments in oncology.
  • The Phosphatidylinositol 3-kinase (PI3K) pathway is integral to cellular functions and implicated in numerous human cancers.
  • Differential expression of PI3K's p110-δ isoform in lymphocytes highlights its role in lymphoma pathogenesis.

Purpose of the Study:

  • To review the role of the PI3K-AKT-mTOR pathway in normal and malignant lymphocytes.
  • To examine the preclinical and clinical development status of inhibitors targeting this pathway.

Main Methods:

  • Literature review of scientific publications.
  • Analysis of preclinical data for PI3K pathway inhibitors.
  • Assessment of clinical trial data for lymphoma treatments.

Main Results:

  • Specific PI3K inhibitors targeting the p110-δ isoform are in clinical trials for lymphoma.
  • Downstream effectors AKT and mTOR are critical in lymphoma, with inhibitors in earlier development.
  • The PI3K-AKT-mTOR axis represents a promising therapeutic target in lymphoid malignancies.

Conclusions:

  • Inhibitors of the PI3K-AKT-mTOR pathway demonstrate significant therapeutic potential in lymphoma.
  • Targeting this pathway offers a more selective approach compared to conventional chemotherapy.
  • Further clinical investigation is warranted for PI3K pathway-targeted agents in oncology.
Keywords:
AKTPI3KlymphomamTORtargeted-therapy

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

945
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K